Seniors with type 2 diabetes or those with diabetic complications were less likely to be hospitalized for heart failure while taking a sodium-glucose co-transporter 2 (SGLT2) inhibitor compared to dipeptidyl peptidase-4 (DPP4) inhibitors, another new class of oral antidiabetic drug, according to a study released in Cardiovascular Diabetology and conducted by Anthem Inc. and HealthCore.
Healthcare advertising agencies need to sharpen their listening skills according to a new HCB Health survey.
A very high percentage of Prior Authorization (PA) requests are approved…but about 40% of these prescriptions are abandoned during the PA process, around 74.4 million prescriptions a year.
GE Healthcare announced FDA 510(k) clearance of an industry-first, patient-assisted mammography device that literally puts women in control of their mammograms.
Teva Pharmaceutical Industries Ltd. announced that the U.S. FDA approved Austedo (deutetrabenazine) tablets for the treatment of tardive dyskinesia in adults.
The U.S. FDA approved Genentech’s Actemra (tocilizumab) intravenous injection for the treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome in patients 2 years of age and older.
Noble, a leader in biopharmaceutical onboarding and device training, announced a global collaboration with BD (Becton, Dickinson and Company), a leading global medical technology company, for developing patient onboarding solutions including demonstration devices.
PACIFIC Communications, the West Coast’s largest healthcare communications agency, announced the return of Associate Creative Director/Copy Kent Sewell.
Outcome Health, which provides health intelligence in moments of care to improve patient outcomes, announced the hiring of its first Chief Engineering Officer, Nandini Ramani.
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and the International Society for Pharmacoepidemiology (ISPE) announced their plans for a one-day conference focused on real-world evidence.
